Crystagen

Supported

Selected academic sources identify Crystagen as the tripeptide Glu-Asp-Pro (EDP), but conflicting commercial sequence claims require identity review.

Supported

A preclinical spleen-aging study reported immune-related effects of Crystagen.

Sources: Molecular aspects of immunoprotective activity of peptides in spleen during aging

Supported

Related thymic-peptide reviews are not direct clinical evidence for Crystagen.

Sources: The use of Thymalin for immunocorrection and molecular aspects of its activity

Supported

No verified human clinical study of a standardized Crystagen product was located.

Supported

Crystagen is generally identified in peer-reviewed Khavinson-lineage literature as the synthetic tripeptide Glu-Asp-Pro, abbreviated EDP. Crystagen must remain separate from Thymalin (a heterogeneous thymic polypeptide preparation), Thymogen (commonly Glu-Trp), Vilon (commonly Lys-Glu), thymosin alpha-1, thymopentin, and other "cytogen," "cytomedin," thymic, or peptide-bioregulator products. Marketplace sources provide conflicting sequences and compositions; the peer-reviewed EDP identity is the approved canonical mapping for this page, while the existence of marketplace inconsistency must remain visible. Free acid, salts, oral products, lyophilized injectable products, and proprietary branded formulations must not be assumed equivalent.

Supported

A 2011 laboratory study evaluated short tripeptides in primary embryonic mesenchymal cells, fibroblasts, human K-562 erythromyelosis cells, and lymphoid-cell systems, reporting differential effects on proliferation, including stimulation of spontaneous proliferation in normal lymphocytes and inhibitory effects in selected embryonic or immortalized cell systems. This was cell-based research; it does not establish immune restoration, infection prevention, cancer treatment, or clinical safety.

Sources: Effect of Tripeptides on Lymphoid and Stem Cells

Supported

Animal and tissue studies from the same research lineage reported effects of Crystagen on markers associated with B-cell immunity and age-related spleen changes; one study reported activation of B-cell-related immunity but no improvement in cellular-renewal processes in the aging spleen. These findings are preclinical, limited, and not independently replicated across multiple research groups.

Sources: Age-Related Molecular Aspects of Immunomodulating Activity of Peptides in the Spleen; Molecular aspects of immunoprotective activity of peptides in spleen during aging

Supported

Reviews of ultrashort peptide bioregulators discuss possible transport through peptide and amino-acid carriers, interactions with DNA or histones, changes in gene-expression accessibility, and tissue-specific regulatory hypotheses. These class-level models do not establish a validated Crystagen receptor, human pharmacokinetics, clinical target engagement, or therapeutic mechanism.

Sources: Peptide regulation of gene expression: a systematic review

Supported

Some regional literature and product materials describe oral Crystagen used together with other short peptides in athletes, with changes in stress-response genes, cytokines, or respiratory-infection frequency. Because Crystagen was administered in a combination and the evidence is not a modern independently replicated randomized Crystagen-specific program, those observations cannot establish Crystagen efficacy.

Supported

Clinical findings involving Thymalin cannot be transferred to Crystagen merely because EDP has been proposed as one constituent or active motif of thymic preparations. A heterogeneous extract and a defined tripeptide are not interchangeable products.

Sources: The use of Thymalin for immunocorrection and molecular aspects of its activity

Supported

No FDA-approved Crystagen drug or indication was identified. Crystagen was not identified on the reviewed current FDA 503A/503B bulk-substance category lists or FDA peptide safety table; absence from those lists does not establish approval, safety, effectiveness, or compounding eligibility. No Crystagen-specific interventional trial was identified in the reviewed ClinicalTrials.gov search. Marketing as a dietary supplement, peptide bioregulator, "cytogen," or research material does not establish drug approval.

Sources: ClinicalTrials.gov Search Portal

Supported

No adequate Crystagen-specific randomized controlled human trial, pharmacokinetic study, dose-ranging study, or repeated-dose safety program was identified. No reliable evidence establishes treatment or prevention of immune deficiency, viral or bacterial infection, cancer or chemotherapy-related immune suppression, autoimmune disease, immunosenescence, athletic overtraining, aging or longevity, or stress-related illness.

Sources: ClinicalTrials.gov Search Portal

Supported

Human safety is inadequately characterized. Important uncertainties include conflicting commercial identity descriptions, limited independent replication, uncertain absorption and bioavailability, free-acid versus salt and formulation differences, immunogenicity and peptide-related impurities, aggregation, sterility and endotoxin risk for injectable preparations, unknown immune overstimulation or suppression, unknown autoimmune and allergy effects, unknown hematologic, hepatic, renal, cardiovascular, reproductive, and oncologic effects, unknown pregnancy, pediatric, and long-term safety, and lack of validated human pharmacokinetic or pharmacodynamic markers. A short three-amino-acid sequence does not automatically establish safety, oral activity, cell penetration, or tissue specificity.

Sources: Effect of Tripeptides on Lymphoid and Stem Cells